PDCD1 and head and neck cancer: The development of immune checkpoint inhibitors (ICIs), such as anti-programmed cell death protein-1 (anti-PD-1) therapies, have demonstrated promising outcomes and improved overall survival in the treatment of advanced head and neck cancer [4,5].